Maintenance chemotherapy in the management of epithelial ovarian cancer (Q38310412)

2 September 2017

1 reference

title

Maintenance chemotherapy in the management of epithelial ovarian cancer (English)

1 reference

2 September 2017

1 reference

ChEBI release 2020-05-28

1 reference

Maurie Markman

1

1 reference

2 September 2017

publication date

1 March 2015

1 reference

Cancer and Metastasis Reviews

2 September 2017

published in

1 reference

2 September 2017

volume

34

1 reference

2 September 2017

issue

1

1 reference

2 September 2017

page(s)

11-17

1 reference

Comparison of intermittent and continuous palliative chemotherapy for advanced colorectal cancer: a multicentre randomised trial

2 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS10555-014-9537-X

Interrupted versus continuous chemotherapy in patients with metastatic breast cancer. The Piedmont Oncology Association

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-014-9537-X

Advanced ovarian adenocarcinoma. A prospective clinical trial of melphalan (L-PAM) versus combination chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-014-9537-X

A prospective randomized comparison of 6 and 12 cycles of cyclophosphamide, adriamycin, and cisplatin in advanced epithelial ovarian cancer: a Danish Ovarian Study Group trial (DACOVA).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-014-9537-X

Randomized prospective trial of 5 versus 10 cycles of cyclophosphamide, doxorubicin, and cisplatin in advanced ovarian carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-014-9537-X

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-014-9537-X

Phase II trial of paclitaxel in patients with progressive ovarian carcinoma after platinum-based chemotherapy: a Gynecologic Oncology Group study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-014-9537-X

Redefining the target: chemotherapeutics as antiangiogenics

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-014-9537-X

Chronic administration of single-agent paclitaxel in gynecologic malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-014-9537-X

A case of chronic paclitaxel administration in ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-014-9537-X

Phase III randomized trial of 12 versus 3 months of maintenance paclitaxel in patients with advanced ovarian cancer after complete response to platinum and paclitaxel-based chemotherapy: a Southwest Oncology Group and Gynecologic Oncology Group tria

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-014-9537-X

Impact on survival of 12 versus 3 monthly cycles of paclitaxel (175 mg/m2) administered to patients with advanced ovarian cancer who attained a complete response to primary platinum-paclitaxel: follow-up of a Southwest Oncology Group and Gynecologic

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-014-9537-X

Detecting an overall survival benefit that is derived from progression-free survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-014-9537-X

Phase III trial of observation versus six courses of paclitaxel in patients with advanced epithelial ovarian cancer in complete response after six courses of paclitaxel/platinum-based chemotherapy: final results of the After-6 protocol 1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-014-9537-X

Topotecan compared with no therapy after response to surgery and carboplatin/paclitaxel in patients with ovarian cancer: Multicenter Italian Trials in Ovarian Cancer (MITO-1) randomized study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-014-9537-X

Randomized phase III trial of topotecan following carboplatin and paclitaxel in first-line treatment of advanced ovarian cancer: a gynecologic cancer intergroup trial of the AGO-OVAR and GINECO.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-014-9537-X

Epidoxorubicin versus no treatment as consolidation therapy in advanced ovarian cancer: results from a phase II study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-014-9537-X

Long-term follow-up of a phase II trial of oral altretamine for consolidation of clinical complete remission in women with stage III epithelial ovarian cancer in the Southwest Oncology Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-014-9537-X

Angiogenesis as a therapeutic target

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-014-9537-X

Phase II trial of bevacizumab in persistent or recurrent epithelial ovarian cancer or primary peritoneal cancer: a Gynecologic Oncology Group Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-014-9537-X

Phase II study of bevacizumab in patients with platinum-resistant ovarian cancer or peritoneal serous cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-014-9537-X

Incorporation of bevacizumab in the primary treatment of ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-014-9537-X

A phase 3 trial of bevacizumab in ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-014-9537-X

OCEANS: a randomized, double-blind, placebo-controlled phase III trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-014-9537-X

Maintenance treatment with interferon for advanced ovarian cancer: results of the Northern and Yorkshire gynaecology group randomised phase III study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-014-9537-X

Randomized trial of adjuvant intraperitoneal alpha-interferon in stage III ovarian cancer patients who have no evidence of disease after primary surgery and chemotherapy: An intergroup study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-014-9537-X

Oregovomab maintenance monoimmunotherapy does not improve outcomes in advanced ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-014-9537-X

Abagovomab as maintenance therapy in patients with epithelial ovarian cancer: a phase III trial of the AGO OVAR, COGI, GINECO, and GEICO--the MIMOSA study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-014-9537-X

Randomized phase III study of erlotinib versus observation in patients with no evidence of disease progression after first-line platin-based chemotherapy for ovarian carcinoma: a European Organisation for Research and Treatment of Cancer-Gynaecologi

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-014-9537-X

Poly(ADP)-ribose polymerase inhibition: frequent durable responses in BRCA carrier ovarian cancer correlating with platinum-free interval

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-014-9537-X

Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-014-9537-X

Somatic mutations in BRCA1 and BRCA2 could expand the number of patients that benefit from poly (ADP ribose) polymerase inhibitors in ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-014-9537-X

Olaparib Maintenance Therapy in Platinum-Sensitive Relapsed Ovarian Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-014-9537-X

10.1007/S10555-014-9537-X

21 January 2018

Identifiers

DOI

1 reference

Dimensions Publication ID

2 September 2017

1014577598

0 references

1 reference